EN DE
Watch Green Cross for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Green Cross (005250) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Green Cross stock KRW 16,072, price KRW 9,410, upside +70.8%, quality 35 out of 100. Rating: strongly undervalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7005250006

GC Green Cross logo Thin data Nov 8, 2026

Green Cross

005250 · KO
Cheap, value-trap risk

The stock costs 41% less than our calculation considers fair.

Fair value 16,072 KRW · Strongly undervalued
Ranks above peers (8/12)
Expensive Growth (revenue 5y +7.4 %/yr in KRW)
Moderate debt
3.2% dividend yield · Watch coverage
Wide range: only 4,894 KRW in the cautious scenario.
Quality 35/100
Loss-making · -4.9% net margin (TTM)
Negative free cash flow
Narrow moat 15/100
Thin data
Watch Green Cross for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

32,054 KRW 9,030 KRW Fair Value 16,072 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 9,030 KRW – 32,054 KRW · fair‑value band 4,894 KRW – 27,249 KRW · the 9,410 KRW price screens below the 16,072 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Green Cross in your weekly email

Every Wednesday you see whether Green Cross is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services.

Show moreShow less

It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille's syndrome.

The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies, and clinical trials. Additionally, the company provides personalized nutrition injections.

The company was formerly known as Green Cross Holdings Corporation and changed its name to GC Corp. in April 2026. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea.

Stock analysis

Green Cross (005250) currently trades at 9,410 KRW, while our model-based Fair Value estimate is 16,072 KRW, implying the stock looks roughly 41% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 80/100, which puts the data coverage at low.

Scenario range: 4,894 KRW (bear) to 27,249 KRW (bull), the price of 9,410 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Green Cross reported revenue of 2.5T KRW in FY2025 versus 1.8T KRW in FY2021, a compound +7.4%/yr. Reported net income was −69.5B KRW in FY2025.

Key figures

Market cap 425B KRW (≈ $314M) Small · P/S ratio 0.17 · EPS (TTM) −2,682 KRW · Dividend yield 3.2% · Net margin −4.9% · Return on equity −8.4% · Return on assets (EBIT) 0.9% (5-year average) · Operating margin 1.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 44% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 71%, 005250 screens cheaper than that median.

Fair Value models

Bear 4,894 KRW Fair Value 16,072 KRW Bull 27,249 KRW
Price 9,410 KRW · Upside +70.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA 4,894 KRW 16,072 KRW 27,249 KRW 61
NCAV (Graham) 1,966 KRW 2,635 KRW 3,933 KRW 54
All 2 models by family
Multiples
EV/EBITDA 4,894 KRW 16,072 KRW 27,249 KRW 61
Asset-Based
NCAV (Graham) 1,966 KRW 2,635 KRW 3,933 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 17
How much profit the company makes from its sales and capital
Quality Growth 37
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 11
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Start year 2020 (pandemic). Over 10 years: +8.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.1% (2020) → 1.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 005250, get fair value alerts →

Compare Green Cross with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside +69.7% · Top 25%
Profitability
Return on assets −1.7% · Above median
Net margin (12 months) −4.9% · Below median
Operating margin (12 months) 1.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) −0.7% · Below median
Dividend yield (12 months) 3.2% · Top 25%
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.47× · Cheapest 25%
P/S (12 months) 0.17× · Cheapest 25%
EV/EBITDA 6.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)74 · sector 97
DIVIDEND (yield)63 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 005250
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 005250
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 005250
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 005250
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 005250
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 005250
argenx SE ARGX $927.21 $908.40 −2% vs 005250
CSL Limited CSL A$200.77 A$183.04 −9% vs 005250
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 005250
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 005250

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Green Cross: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Green Cross Fair Value". https://www.fairvalue-calculator.com/stock/005250

Frequently asked questions

Is Green Cross (005250) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 16,072 KRW versus a price of 9,410 KRW, about +71% upside (undervalued).
What is the fair value of 005250?
Our model-based fair value for Green Cross is 16,072 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 9,410 KRW.
What is the quality score of 005250?
Green Cross has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Green Cross (005250)?
Our model-based price target is the fair value of 16,072 KRW (as of Nov 8, 2026) from 2 valuation models. Cautious scenario 4,894 KRW, optimistic scenario 27,249 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Green Cross stock forecast for 2026?
Our models put fair value at 16,072 KRW, about +71% upside versus a price of 9,410 KRW (undervalued). Cautious scenario 4,894 KRW, optimistic scenario 27,249 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Green Cross (005250)?
Green Cross reported trailing-twelve-month revenue of about 2.5T KRW (latest available figure, as of Nov 8, 2026).
Does Green Cross pay a dividend?
Green Cross currently shows a dividend yield of 3.19% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Green Cross (005250) and when is the ex-dividend date?
Green Cross pays a dividend of 300.00 KRW per share a year, a dividend yield of 3.2%. The last ex-dividend date was Mar 30, 2026. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Green Cross (005250)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Green Cross it is 16,072 KRW per share (as of Nov 8, 2026), against a price of 9,410 KRW. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Green Cross stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 005250 trades below its calculated fair value: price 9,410 KRW, fair value 16,072 KRW, a gap of about +71% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 005250?
No. The price is what the market pays today (9,410 KRW); the fair value is what the company's own numbers justify (16,072 KRW). For Green Cross the two are 6,662 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Green Cross worth?
The market values Green Cross at about 425B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 9,410 KRW; our models calculate a fair value of 16,072 KRW per share.
What do the bullish and bearish scenarios say about 005250?
Our models span a range for Green Cross: cautious scenario 4,894 KRW, base 16,072 KRW, optimistic 27,249 KRW per share (as of Nov 8, 2026, price 9,410 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Green Cross (005250)?
Balance-sheet figures for Green Cross (as of Nov 8, 2026): return on equity −8.4%, debt of 0.53 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is 005250 from its 52-week high?
Green Cross trades at 9,410 KRW, about 44% below its 52-week high of 16,809 KRW and 4% above the low of 9,030 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 16,072 KRW is for.
Which stocks are comparable to Green Cross?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Green Cross stock attractive at the current price?
The data as of Nov 8, 2026: price 9,410 KRW, calculated fair value 16,072 KRW (+71%), Quality Score 35/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 005250 calculated?
We run Green Cross through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of 16,072 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Green Cross currently trades 41% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Green Cross (005250)?
The closing price on Nov 9, 2026 was 9,410 KRW. Our model-based fair value is 16,072 KRW, about +71% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Green Cross right now?
The large discount to fair value meets weak quality (35/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide (4,894 KRW to 27,249 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Green Cross

How large is the market capitalisation of Green Cross (005250)?
The market capitalisation of Green Cross is 425B KRW (≈ $314M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Green Cross (005250)?
The price-to-sales ratio of Green Cross is 0.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Green Cross (005250)?
Earnings per share at Green Cross are −2,682 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Green Cross (005250)?
The dividend yield of Green Cross is 3.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Green Cross (005250)?
The net margin of Green Cross is −4.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Green Cross (005250)?
The return on equity (ROE) of Green Cross is −8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Green Cross (005250)?
On an EBIT basis the return on assets of Green Cross is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Green Cross (005250)?
The operating margin of Green Cross is 1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Green Cross (005250)?
Revenue at Green Cross is growing −0.7% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Green Cross (005250)?
Earnings per share at Green Cross are growing −95.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Green Cross (005250) generate?
The free cash flow of Green Cross is −126B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Green Cross (005250) carry?
The net debt of Green Cross is 1.3T KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Green Cross in the live analysis

One click puts Green Cross on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.